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DOI 10.1016/j.ccr.2008.04.021VEGFRs are primarily expressed by endothelial cells but are also
expressed by nonendothelial cell types, including cancer cells
(Witte et al., 2002; Li et al., 2003; Van Trappen et al., 2003; Wu
et al., 2003; Su et al., 2007). VEGFR-3 influences the potential
for a lymphangiogenic response (Alitalo and Carmeliet, 2002;
Joukov et al., 1996; Skobe et al., 2001). Recent studies have in-
dicated that VEGFR-3 is also expressed in a variety of human
malignancies and that the VEGF-C/VEGFR-3 axis contributes
to tumor progression (Dias et al., 2002; Marchio et al., 1999;
Masood et al., 2003; Mylona et al., 2007; Van Trappen et al.,
2003; Witte et al., 2002). We provided evidence in a recent study
that the VEGF-C/VEGFR-3 axis enhances cancer cell mobility
and invasion capabilities and promotes cancer cell metastasis
(Su et al., 2006). Petrova et al. questioned the specificity of the
VEGFR-3 antibody used in our previous study and the validity
of our conclusion (Petrova et al., 2008), and we have taken their
concerns to heart. Here we provide additional data to support
our previous conclusions.
Petrova et al. claim that the antibody used in our previous
study (Su et al., 2006) may detect nonspecific antigens, while
their antibodies are more specific. To resolve these concerns,
we used the antibody we used before (MAB3491 purchased
from R&D) and one of the antibodies used by Petrova et al.
(9D9F9 purchased from Chemicon as MAB 3757) to detect
pure recombinant human VEGFR-3 protein (rhVEGFR-3) using
western blot analysis. We found that both antibodies detected
the unglycosylated (112 kDa) and glycosylated (160 kDa)
forms of recombinant human VEGFR-3 protein in a dose-depen-
dent manner (Figure 1A). Both antibodies also detected similar
bands higher than 170 kDa. Furthermore, both antibodies de-
tected endogenous VEGFR-3 in various cancer cell lines and,
as expected, in human dermal microvascular endothelial cells
(HDMEC) (Figure 1B), as well as VEGFR-3 ectopically expressed
in cancer cell lines (Figure S1A available online). By immuno-
precipitation-immunoblotting analysis, we found that VEGFR-3
protein can be immunoprecipitated by both antibodies (Fig-
ure 1C). Using immunofluorescence staining, VEGFR-3 protein
in A549 lung cancer cells and in human lymphatic microvascular
endothelial cells (HLMEC) was detected by both antibodies
(Figure S1B). These data suggest that the sensitivity andspecificity of 9D9F9 antibody and MAB3491 antibody are
comparable.
A similar pattern of proteins were immunoprecipitated by both
antibodies as detected by SDS-PAGE followed by staining with
SimplyBlue SafeStain (purchased from Invitrogen) (Figure 1D).
The 125 kDa bands were subjected to in-gel digestion and
PMF using the nanoLC/MS/MS analysis for protein identification
(Table S1). The representative peptide peaks from MS/MS anal-
ysis were detected as human VEGFR-3 protein precursor in the
immunoprecipitant of either 9D9F9 antibody or MAB3491 anti-
body (Figure S2). The search results indicated that these proteins
showed the best match, with a protein score of greater than or
equal to 1008, considered to be significant using the MASCOT
search algorithm (Table S1). There was no significant difference
between the data from the MS/MS analysis of immunopre-
cipitants using the 9D9F9 antibody and the data from the analy-
sis using the MAB3491 antibody. In agreement with the results
from Petrova et al., some cancer cell lines do not express
VEGFR-3; for example, we can not detect the expression of
VEGFR-3 in BT474 cells using either antibody (Figure 1E).
Together, these data indicated that VEGFR-3 is expressed in
certain cancer cells, and that MAB3491 and 9D9F9 antibodies
recognize human VEGFR-3.
To investigate the expression of VEGFR-3 mRNA in cancer
cells, we performed RT-PCR using three different sets of primers
and clearly detected the presence of VEGFR-3 mRNA (Fig-
ure S3). Furthermore, we used absolute quantitative real-time
RT-PCR to determine levels of VEGFR-3 mRNA expressed in
HDMEC and cancer cell lines (Table S2). The expression of
VEGFR-3mRNA in BT474, MDA-MB-453, and HBL100 cell lines
were undetectable under the same condition (Table S2). To
investigate whether our A549 cells were contaminated with lym-
phatic endothelial cells, we analyzed the expression of a lym-
phatic endothelial marker, LYVE-1, in A549 cells, HDMEC, and
purified HLMEC (at least 95% double-positive for CD31 and po-
doplanin by flow cytometry analysis). As shown in Figures S1C
and S1D, VEGFR-3 is expressed in all three, whereas LYVE-1
is expressed only in HDMEC and HLMEC but not in A549 cells.
These data indicated that VEGFR-3 transcripts are indeed
expressed in some cancer cells.Cancer Cell 13, 557–560, June 2008 ª2008 Elsevier Inc. 557
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A549 cells is consistent with the presence of a VEGF-C/VEGFR-
3 autocrine loop (Su et al., 2006). To study the role of VEGF-C/
VEGFR-3 axis in the invasiveness of cancer cells, expression
of VEGF-C in A549 cells was knocked down using VEGF-C-spe-
cific siRNA. Transfection with VEGF-C-specific siRNA de-
creased the expression of VEGF-C in A549 cells (Figure 1F)
and reduced the phosphorylation of VEGFR-3 (Figure 1G).
Knockdown of VEGF-C also reduced the migratory and invasive
activities of A549 cells in a dose-dependent manner (Figures 1H
and 1I, lane 1 versus lanes 3 and 4), whichwere restored by treat-
ment with recombinant human VEGF-C protein (Figures 1H and
1I, lane 4 versus lanes 5 and 6). Likewise, transfection of A549
cells with VEGFR-3-specific siRNA to decrease the expression
of VEGFR-3 (Figure 1F) reduced their migratory and invasive ac-
tivities (Figures 1H and 1I, lanes 7 and 8). Similar results were ob-
tained using the MDA-MB-231 cell line (Figure S4). In addition to
using pooled siRNAs, we also found similar results in transfec-
tion of A549 cells with two VEGF-C- or VEGFR-3-specific siRNAs
individually (Figure S5). These findings strongly support our pre-
vious conclusion that the VEGF-C/VEGFR-3 axis is actively
involved in regulating the migratory and invasive activities of
cancer cells.
We agree with the points raised by Petrova et al. that careful
characterization of antibodies is very important, especially
when they produce unexpected results. In our hands, both
9D9F9 antibody and MAB3491 antibody can detect VEGFR-3
expression in several cancer cell lines in addition to HDMEC.
We have provided additional data to support our earlier con-
clusion that the VEGF-C/VEGFR-3 axis plays a role in cancer
cell mobility. It is unclear why our results are different from those
of Petrova et al., but different cell culture conditions might have
contributed to this difference. Our findings and other studies
support that VEGFR-3 is expressed not only in endothelial cells
but also in some nonendothelial cells, including some cancer
cells. The VEGF-C/VEGFR-3 axis may have many undefined
functions and mediate tumor progression via many as yet un-
known molecular mechanisms; thus, further study of the axis is
needed.SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, five
supplemental figures, and three supplemental tables and can be found with
this article online at http://www.cancercell.org/cgi/content/full/13/6/557/
DC1/.
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